Ascletis Pharma Inc - Asset Resilience Ratio

Latest as of December 2025: 22.13%

Ascletis Pharma Inc (2VJ) has an Asset Resilience Ratio of 22.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 2VJ strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€457.36 Million

≈ $534.70 Million USD Cash + Short-term Investments

Total Assets

€2.07 Billion

≈ $2.42 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Ascletis Pharma Inc's Asset Resilience Ratio has changed over time. See how leveraged is Ascletis Pharma Inc's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Ascletis Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Ascletis Pharma Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€457.36 Million	22.13%
Total Liquid Assets	€457.36 Million	22.13%

Asset Resilience Insights

Good Liquidity Position: Ascletis Pharma Inc maintains a healthy 22.13% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Ascletis Pharma Inc Industry Peers by Asset Resilience Ratio

Compare Ascletis Pharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Ascletis Pharma Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Ascletis Pharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	22.13%	€457.36 Million ≈ $534.70 Million	€2.07 Billion ≈ $2.42 Billion	-28.79pp
2024-12-31	50.92%	€1.08 Billion ≈ $1.26 Billion	€2.12 Billion ≈ $2.48 Billion	-28.14pp
2023-12-31	79.06%	€1.97 Billion ≈ $2.30 Billion	€2.49 Billion ≈ $2.91 Billion	+78.63pp
2022-12-31	0.42%	€11.20 Million ≈ $13.09 Million	€2.66 Billion ≈ $3.11 Billion	+0.24pp
2021-12-31	0.18%	€5.20 Million ≈ $6.08 Million	€2.83 Billion ≈ $3.31 Billion	-14.33pp
2017-12-31	14.51%	€143.83 Million ≈ $168.15 Million	€991.25 Million ≈ $1.16 Billion	+13.46pp
2016-12-31	1.05%	€5.61 Million ≈ $6.56 Million	€536.26 Million ≈ $626.95 Million	--

pp = percentage points

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$1.32 Billion

€1.13 Billion EUR

Market Cap Rank

#7882 Global

#1051 in Germany

Share Price

€1.07

Change (1 day)

+0.00%

52-Week Range

€0.90 - €1.99

All Time High

€1.99